Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия; 2 Частое учреждение здравоохранения «Центральная клиническая больница «РЖД-Медицина», Москва, Россия; 3 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия;
Список исп. литературыСкрыть список 1. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 18 (1): 5–66. DOI: 10.15829/1728-8800-2019-1-5-66 [Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019; 18 (1): 5–66. DOI: 10.15829/1728-8800-2019-1-5-66 (in Russian).] 2. Дедов И.И., Шестакова М.В., Мельниченко Г.А. и др. Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний». Ожирение и метаболизм. 2021; 18 (1): 5–99. DOI:10.14341/omet12714 [Dedov I.I., Shestakova M.V., Melnichenko G.A. et al. Interdisciplinary Clinical Practice Guidelines "Management of obesity and its comorbidities". Obesity and metabolism. 2021; 18 (1): 5–99. DOI:10.14341/omet12714 (in Russian).] 3. Violan C, Foguet-Boreu Q, Flores-Mateo G et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One 2014; 9 (7): 1–9. DOI: 10.1371/journal.pone.0102149 4. Jeong D, Kim J, Lee H et al. Association of Cardiometabolic Multimorbidity Pattern with Dietary Factors among Adults in South Korea. Nutrients 2020; 12 (9): 1–15. DOI: 10.3390/nu12092730 5. Баланова Ю.А., Шальнова С.А., Деев А.Д. и др. Ожирение в российской популяции – распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018; 6: 123–30. DOI: 10.15829/1560-4071-2018-6-123-130 [Balanova Yu.A., Shalnova S.A., Deev A.D. et al. Obesity in Russian population – prevalence and association with the non-communicable diseases risk factors. Russian Journal of Cardiology. 2018; 6: 123–30. DOI: 10.15829/1560-4071-2018-6-123-130 (in Russian).] 6. Targher G, Byrne CD, Lonardo A et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol 2016; 65 (3): 589–600. DOI: 10.1016/j.jhep.2016.05.013 7. Cai J, Zhang XJ, Ji YX et al. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circ Res 2020; 126 (5): 679–704. DOI: 10.1161/CIRCRESAHA.119.316337 8. Артериальная гипертензия у взрослых. Клинические рекомендации, утвержденные Минздравом России. М., 2020. [Arterial hypertension in adults. Clinical recommendations approved by the Ministry of Health of Russia. Moscow, 2020. URL: https://cr.minzdrav.gov.ru/recomend/62_2 (in Russian).] 9. Ожирение. Клинические рекомендации, утвержденные Минздравом России. М., 2020. [Obesity. Clinical recommendations approved by the Ministry of Health of Russia. Moscow, 2020. URL: https://cr.minzdrav.gov.ru/ recomend/28_2 (in Russian).] 10. Неалкогольная жировая болезнь печени у взрослых. Клинические рекомендации, утвержденные Минздравом России. М., 2020. [Non-alcoholic fatty liver disease in adults. Clinical recommendations approved by the Ministry of Health of Russia. Moscow, 2020. URL: https://cr.minzdrav.gov.ru/recomend/748_1 (in Russian).] 11. Simental-Mendía M, Sánchez-García A, Simental-Mendía LE. Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. Br J Clin Pharmacol 2020; 86 (8): 1476–88. DOI: 10.1111/bcp.14311 12. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36 (Suppl. 1): S3–S12. DOI: 10.1016/S2210-7401(12)70015-3 13. Simental-Mendía LE, Simental-Mendía M, Sánchez-García A et al. Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Lipids Health Dis 2019; 18 (1): 88. DOI: 10.1186/ s12944-019-1041-4 14. Gianturco V, Troisi G, Bellomo A et al. Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety. Hepatol Int 2013; 7 (2): 570–6. DOI: 10.1007/s12072-012-9387-y 15. Leuschner UF, Lindenthal B, Herrmann G et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52 (2): 472–9. DOI: 10.1002/hep.23727 16. Arab JP, Karpen SJ, Dawson PA et al. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology 2017; 65 (1): 350–62. DOI: 10.1002/hep.28709 17. Hatano R, Kawaguchi K, Togashi F et al. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2kd/kd Mice. Biol Pharm Bull 2017; 40 (1): 34–42. DOI: 10.1248/bpb.b16-00529 18. Lukivskaya O, Patsenker E, Buko VU. Protective effect of ursodeoxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: link with oxidative stress. Life Sci 2007; 80 (26): 2397–402. DOI: 10.1016/j.lfs.2007.02.042 19. Oh AR, Bae JS, Lee J et al. Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice. BMB Rep 2016; 49 (2): 105–10. DOI: 10.5483/bmbrep.2016.49.2.173 20. Sokolovic D, Nikolic J, Kocic G et al. The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation. Drug Chem Toxicol 2013; 36 (2): 141–8. DOI: 10.3109/01480545.2012.658919 21. Martsevich SYu, Kutishenko NP, Drozdova LYu et al. Study of ursodeoxycholic acid influence on efficacy and safety of statin therapy in patients with diseases of the liver, gall bladder and/or biliary tract (the RAKURS study). Rat Pharm Cardiol 2014; 10 (2): 147–52. DOI: 10.20996/1819-6446-2014-10-2-147-152 22. Nadinskaia M, Maevskaya M, Ivashkin V et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2021; 27 (10): 959–75. DOI: 10.3748/wjg.v27.i10.959 23. Пирогова И.Ю., Яковлева С.В., Неуймина Т.В. и др. Влияние препарата УрСосан на стеатоз и Фиброз печени, а также показатЕли метаболического синдРома у больных с неалкогольной жировой болезнью печени: сравнительное исследование «СФЕРА». Гастроэнтерология (Прил. к журн. Consilium Medicum). 2018; 1: 7–14. DOI: 10.26442/2414-3529_2018.1.7-14 [Pirogova I.Yu., Yakovleva S.V., Neujmina T.V. et al. Pleiotropic effects of Ursosan in non-alcoholic fatty liver disease and metabolic syndrome. Gastroenterology (Suppl. Consilium Medicum). 2018; 1: 7–14. DOI: 10.26442/2414-3529_2018.1.7-14 (in Russian).]